Status:
TERMINATED
Enzalutamide Treatment in COVID-19
Lead Sponsor:
Andreas Josefsson
Collaborating Sponsors:
Umeå University
Sahlgrenska University Hospital
Conditions:
COVID-19
Corona Virus Infection
Eligibility:
All Genders
50+ years
Phase:
PHASE2
Brief Summary
COVID-19 is a disease with high rate of morbidity if symptomatic. There is a great need of treatments to decrease the severity. The vast majority of patients needing intensive care are men, and this m...
Eligibility Criteria
Inclusion
- Positive COVID-19 test
- Mild to severe symptoms of COVID-19
- Hospitalization
- WHO performance status 0-3
- Age above or equal to 50 years
- Can understand all the requirements of the study, provide informed consent, and provide authorization of use and disclosure of personal health information.
- Estimated expected survival of 1 year (excluding symptoms due to COVID-19)
Exclusion
- Severe allergy to Enzalutamide
- Pregnant or breast-feeding women
- Need of immediate mechanical ventilation
- Current medication includes enzalutamide treatment
- Stroke or Transitory Ischemic attack in medical history
- Treatment for HIV
- Treatment with tamoxifen
- Treatment with immunosuppressive agents
- Severe immunosuppressive disease
- Treatment with warfarin or NOAC (Non-vitamin K-antagonist anticoagulants)
- Previous seizure in medical history
- Other serious illness or medical condition
- Unstable cardiovascular disease
Key Trial Info
Start Date :
July 15 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 29 2021
Estimated Enrollment :
42 Patients enrolled
Trial Details
Trial ID
NCT04475601
Start Date
July 15 2020
End Date
May 29 2021
Last Update
June 2 2022
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Anders Bjartell
Malmo, Skåne County, Sweden
2
Ryhovs Hospital
Jönköping, Småland, Sweden
3
Sahlgrenska University Hospital
Gothenburg, Sweden
4
Linköping University Hospital
Linköping, Sweden